JCI Insight - Protein expression of the gp78 E3-ligase predicts poor breast cancer outcome based on race

Clinical Trials

JCI Insight - Protein expression of the gp78 E3-ligase predicts poor breast cancer outcome based on race

By FYH News Team

Published on June 1, 2022

[ad_1]

Sandeep K. Singhal,¹

Jung S. Byun,²

Tingfen Yan,²

Ryan Yancey,³

Ambar Caban,³

Sara Gil Hernandez,²

Sediqua Bufford,⁴

Stephen M. Hewitt,⁵

Joy Winfield,³

Jaya Sarin Pradhan,³

Vesco Mustkov,³

Jasmine A. McDonald,⁶

Eliseo J. Pérez-Stable,²

Anna Maria Napoles,²

Nasreen Vohra,⁷

Adriana De Siervi,⁸

Clayton Yates,⁹

Melissa B. Davis,¹⁰

Mei Yang,¹¹

Yien Che Tsai,¹¹

Allan M. Weissman,¹¹ and

Kevin Gardner³

Published May 31, 2022
–

More info

View PDF

Abstract

Women of African ancestry suffer higher rates of breast cancer mortality compared to all other groups in the United States. Though the precise reasons for these disparities remain unclear, many recent studies have implicated a role for differences in tumor biology. Using an epitope-validated antibody against the endoplasmic reticulum-associated degradation (ERAD) E3 ubiquitin ligase, gp78, we show that elevated levels of gp78 in patient breast cancer cells predict poor survival. Moreover, high levels of gp78 are associated with poor outcomes in both ER-positive and ER-negative tumors, and breast cancers expressing elevated amounts of gp78 protein are enriched in gene expression pathways that influence cell cycle, metabolism, receptor-mediated signaling, and cell stress response pathways. In multivariate analysis adjusted for subtype and grade, gp78 protein is an independent predictor of poor outcomes in women of African ancestry. Furthermore, gene expression signatures, derived from patients stratified by gp78 protein expression, are strong predictors of recurrence and pathological complete response in retrospective clinical trial data and share many common features with gene sets previously identified to be overrepresented in breast cancers based on race. These findings implicate a prominent role for gp78 in tumor progression and offer new insights into our understanding of racial differences in breast cancer outcomes.

[ad_2]

Source link

Features

Download and distribute powerful vaccination QI resources for your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.